Synapse - Hematology-Oncology Fellows

Results (1415)

Epcoritamab monotherapy in patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): Results from CLL expansion and optimization cohorts of EPCORE CLL-1

Meeting Abstract

Danilov, A.; Fakhri, B.; Awan, F. T.; Bentzen, H. H.; Eradat, H. A.; Niemann, C. U.; Offner, F.; Poulsen, C. B.; Hoeyer, T.; Bellido, M.; more...
Blood (2024)

Fulltext@MSK | Save

Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center

Meeting Abstract

Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
Blood (2024)

Fulltext@MSK | Save

Cost-effectiveness of allogeneic hematopoietic stem cell transplantation versus consolidation chemotherapy for patients with intermediate risk acute myeloid leukemia

Meeting Abstract

Alhajahjeh, A.; Patel, K.; Shallis, R. M.; Podoltsev, N. A.; Kewan, T.; Stempel, J. M.; Mendez, L.; Huntington, S. F.; Stahl, M.; Zeidan, A. M.; more...
Blood (2024)

Fulltext@MSK | Save

Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance

Meeting Abstract

Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; Garcés, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
Blood (2024)

Fulltext@MSK | Save

A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma

Meeting Abstract

Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
Blood (2024)

Fulltext@MSK | Save

Impact of response to hypomethylating agent-based therapy on survival outcomes in the context of baseline clinical-molecular risk and transplant status in patients with myelodysplastic syndromes/neoplasms (MDS): An analysis from the international consortium for MDS (icMDS) validate database

Meeting Abstract

Rolles, B.; Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stempel, J. M.; Lanino, L.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; more...
Blood (2024)

Fulltext@MSK | Save

The predictive value of cell-of-origin subtype by Hans algorithm in 718 patients with large B cell lymphoma receiving polatuzumab vedotin

Meeting Abstract

Scheffer Cliff, E. R.; Pelaez, G. D.; Wan, F.; Iyengar, V.; Zhou, J.; Chung, K.; Abdel-Razeq, N.; Major, A.; Allen, J. M.; Sharp, J.; more...
Blood (2024)

Fulltext@MSK | Save

Cross-talk between leukemic blasts and T cells drives targetable T cell dysfunction in the AML tumor microenvironment

Meeting Abstract

DeWolf, S.; Ceglia, N.; Zatzman, M.; Gipson, B.; Elhanati, Y.; Katsamakis, Z.; Lees, H.; Weis, K.; Yepes, G.; Oliveira, B.; more...
Blood (2024)

Fulltext@MSK | Save

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Meeting Abstract

Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
Blood (2024)

Fulltext@MSK | Save

Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDAC™ degrader, in patients with non-Hodgkin's lymphoma

Meeting Abstract

Horwitz, S.; Jain, S.; Soumerai, J. D.; Tees, M. T.; Stuver, R.; Ali, A.; Leahy, L.; Lobbardi, R.; Chu, R.; Hurh, E.; more...
Blood (2024)

Fulltext@MSK | Save